We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Gadobutrol Injection Approved for MRI of the Central Nervous System

By MedImaging International staff writers
Posted on 28 Mar 2011
A 1.0 molar macrocyclic gadolinium-based contrast agent (GBCA) for intravenous use in diagnostic magnetic resonance imaging (MRI) in adults and children age two and older has been designed to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system (CNS).

Bayer HealthCare Pharmaceuticals (Berlin, Germany) reported that the US Food and Drug Administration approved Bayer's gadobutrol injection Gadavist (gadobutrol). Gadavist is known as Gadovist outside the United States and is approved in over 60 countries.

"We are very happy to offer gadobutrol injection to US healthcare providers, an important new option for contrast-enhanced MRI of the CNS,” said Kemal Malik, MD, head of global development and member of the Bayer HealthCare Executive Committee. Our MR contrast agents are some of the most widely used today, and Bayer is proud to be a world leader in diagnostic imaging.”

MRI has been used by physicians for more than 25 years to create detailed images of the human anatomy. Contrast agents are often used to better visualize anatomic structures and pathologies.

Data submitted by Bayer for approval included results from two phase-III studies that confirmed the efficacy and safety of 1.0 molar gadobutrol injection in contrast enhanced MRI of the CNS. The first phase III study compared the efficacy of combined gadobutrol-enhanced images plus unenhanced (without injection of contrast agent) images to unenhanced images alone. The second phase III study used a crossover design with an active control, gadoteridol, to also compare the efficacy of the combined gadobutrol-enhanced plus unenhanced images to unenhanced images alone, as well as to validate noninferiority of combined gadobutrol imaging versus combined gadoteridol imaging.

Related Links:
Bayer HealthCare Pharmaceuticals



Multi-Use Ultrasound Table
Clinton
Wall Fixtures
MRI SERIES
3T MRI Scanner
MAGNETOM Cima.X
Radiology Software
DxWorks

Channels

Nuclear Medicine

view channel
Image: The diagnostic tool could improve diagnosis and treatment decisions for patients with chronic lung infections (Photo courtesy of SNMMI)

Novel Bacteria-Specific PET Imaging Approach Detects Hard-To-Diagnose Lung Infections

Mycobacteroides abscessus is a rapidly growing mycobacteria that primarily affects immunocompromised patients and those with underlying lung diseases, such as cystic fibrosis or chronic obstructive pulmonary... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.